XELLIA PHARMS APS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and what generic alternatives to XELLIA PHARMS APS drugs are available?
XELLIA PHARMS APS has sixteen approved drugs.
There are eight US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.
Summary for XELLIA PHARMS APS
International Patents: | 50 |
US Patents: | 8 |
Tradenames: | 10 |
Ingredients: | 10 |
NDAs: | 16 |
Drugs and US Patents for XELLIA PHARMS APS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xellia Pharms Aps | VORICONAZOLE | voriconazole | INJECTABLE;INTRAVENOUS | 208562-001 | Mar 9, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Xellia Pharms Aps | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 205923-002 | Jul 2, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-006 | May 13, 2020 | RX | Yes | Yes | 11,628,200 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELLIA PHARMS APS Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3675815 | ⤷ Sign Up |
Denmark | 3542812 | ⤷ Sign Up |
Eurasian Patent Organization | 201790997 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XELLIA PHARMS APS Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1115417 | SPC/GB06/024 | United Kingdom | ⤷ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
1115417 | 22/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
1280520 | 92678 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.